CA2583079A1 - Methods using glycosaminoglycans for the treatment of kidney disease - Google Patents

Methods using glycosaminoglycans for the treatment of kidney disease Download PDF

Info

Publication number
CA2583079A1
CA2583079A1 CA002583079A CA2583079A CA2583079A1 CA 2583079 A1 CA2583079 A1 CA 2583079A1 CA 002583079 A CA002583079 A CA 002583079A CA 2583079 A CA2583079 A CA 2583079A CA 2583079 A1 CA2583079 A1 CA 2583079A1
Authority
CA
Canada
Prior art keywords
day
composition
amount
administered
sulodexide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002583079A
Other languages
English (en)
French (fr)
Inventor
Michael Spero
Michael S. Weiss
Jeffrey B. Kopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of CA2583079A1 publication Critical patent/CA2583079A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002583079A 2004-10-01 2005-10-03 Methods using glycosaminoglycans for the treatment of kidney disease Abandoned CA2583079A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61547204P 2004-10-01 2004-10-01
US60/615,472 2004-10-01
US62233204P 2004-10-26 2004-10-26
US60/622,332 2004-10-26
PCT/US2005/035790 WO2006039709A1 (en) 2004-10-01 2005-10-03 Methods using glycosaminoglycans for the treatment of kidney disease

Publications (1)

Publication Number Publication Date
CA2583079A1 true CA2583079A1 (en) 2006-04-13

Family

ID=36142893

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002583079A Abandoned CA2583079A1 (en) 2004-10-01 2005-10-03 Methods using glycosaminoglycans for the treatment of kidney disease

Country Status (6)

Country Link
EP (1) EP1804810A4 (de)
JP (1) JP2008515807A (de)
AU (1) AU2005292202A1 (de)
CA (1) CA2583079A1 (de)
IL (1) IL182353A0 (de)
WO (1) WO2006039709A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616230A1 (en) * 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
MX2008008213A (es) 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
EP2765984B1 (de) * 2011-10-11 2019-07-31 HemaFlo Therapeutics, Inc. Verfahren zur behandlung einer akuten nierenverletzung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
IT1270846B (it) * 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
US20010005720A1 (en) * 1995-06-07 2001-06-28 U.S.A. As Represented By The Secretary Department Of Health And Human Services Method of treating chronic progressive vascular scarring diseases
US20030013680A1 (en) * 2001-06-12 2003-01-16 Keryx Methods using glycosaminoglycans for the treatment of nephropathy

Also Published As

Publication number Publication date
EP1804810A1 (de) 2007-07-11
AU2005292202A1 (en) 2006-04-13
EP1804810A4 (de) 2008-02-27
JP2008515807A (ja) 2008-05-15
IL182353A0 (en) 2008-04-13
WO2006039709A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
EP1392329B1 (de) Verwendung von sulodexid zur behandlung von reizdarm
US20080070862A1 (en) Methods using glycosaminoglycans for the treatment of nephropathy
AU2002304265A1 (en) Use of sulodexide for the treatment of inflammatory bowel disease
EP2371371B1 (de) Zusammensetzung zur prävention von adhäsion
US20100266709A1 (en) Compositions and Methods for Treating Burns
US7604797B2 (en) Compositions and methods for treating burns
CA2365767A1 (en) Angiogenesis inhibition
EP3474897B1 (de) Cilastatin zur verwendung bei der behandlung von sepsis
JP2001519392A (ja) シクロスポリンおよびタクロリムスによって起こる腎臓毒の防止方法
CA2583079A1 (en) Methods using glycosaminoglycans for the treatment of kidney disease
JP2000309538A (ja) 子癇前症および関連疾患の新規治療法
US20240050464A1 (en) Therapeutic Composition and Methods
CN114727976A (zh) PPAR-δ激动剂在肾脏疾病治疗中的用途
KR100815287B1 (ko) 당뇨성 신장병의 치료에 슐로덱사이드를 사용하는 방법 및조성물
US20070173479A1 (en) Methods Using Sulodexide for the Treatment of Bladder Disease
CA2502510A1 (en) Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
JP2006519817A (ja) 新しい医薬
Milani Sulodexide: Review of recent clinical efficacy data
AU2002311591A1 (en) Use of glycosaminoglycans for the treatment of HIV-associated nephropathy
CH702779B1 (fr) Utilisation de polysulfate de pentosan sodique dans la préparation d'un médicament pour le traitement de la néphropathie diabétique.
WO2008060567A1 (en) Glycosaminoglycan formulations in the treatment of vascular disease

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20090903